Areas of interest
Our partnering areas of interest are predominantly focused on three core disease areas which include cardiovascular & metabolic disease, respiratory, inflammation & autoimmune disease, and oncology. We remain interested but more opportunistic in partnering in the areas of infection and neuroscience. We are also actively seeking collaborations in personalised healthcare and biomarkers, and innovative science and technologies.
Through MedImmune, our biologics arm, we have world-class capabilities in the research, development, manufacturing and commercialisation of large molecules to complement our small molecule capabilities. MedImmune’s areas of partnering interest mirror those of AstraZeneca in terms of therapeutic areas and we are integrated in our approach to partnering. More information about MedImmune can be found on their website.
Areas of interest & partnering leadership team
For more details on our areas of interest and the details of the leadership partnering team click on the ‘+’ symbol on each panel.
Cardiovascular & Metabolic Diseases
AstraZeneca is a leader in the treatment of Cardiovascular and Metabolic Disease and is committed to delivering new innovative medicines that make a difference to patients and society. Our research focuses on small molecule and biologics for disease areas including diabetes and diabetic complications, including diabetic nephropathy, cardiovascular diseases, including cardiac regeneration, atherosclerosis (cerebral, carotid, aortic, coronary, and peripheral), heart failure (systolic and diastolic), cardiorenal syndrome, renal injury (acute and chronic), metabolic syndrome, dyslipidemia, systemic inflammatory states (cellular and humoral affecting metabolism and the cardiovascular/renal systems).
Partnering leadership team
| Small molecule business development | R&D Strategy Head | Biologics business development |
|---|---|---|
| Christoph Pittius
VP SPBD, CVGI |
James Hall
VP Strategy, CVGI |
Eric Victory
VP, Corporate Development |
Respiratory, Inflammation & Autoimmune
AstraZeneca has a 40-year history in small molecule research and a best-in-class pipeline of biologic candidates for respiratory, inflammatory and autoimmune diseases. Our goal is to lead the advancement of innovative medicines with greater efficacy, improved safety and enhanced convenience. We are particularly interested in asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, systemic lupus erythematosus and novel inhalation approaches.
Partnering leadership team
| Small molecule business development | R&D Strategy Head | Biologics business development |
|---|---|---|
|
VP SPBD, R&I and New Opportunities |
VP Strategy, R&I |
Associate Director, Business Development |
Oncology
For more than 30 years, AstraZeneca has remained committed to pushing the boundaries of cancer research and delivering the cancer therapies of tomorrow. We’re taking an innovative patient-based approach to treatment, and drawing on partnerships across the globe with academia, governments, scientific organisations and patient groups, as well as other biopharmaceutical companies. Our small and large molecule research focuses on cancer of the breast, prostate, gastrointestinal tract, lung, as well as haematological malignancies, “niche” cancers, novel technologies and biomarkers.
Partnering leadership team
| Small molecule business development | R&D Strategy Head | Biologics business development |
|---|---|---|
|
VP SPBD, Oncology and STL |
VP Strategy, Oncology |
Director, Business Development |
Infection
Our Infection group aims to discover and develop effective, targeted therapies to address unmet needs in serious bacterial, fungal or viral infections and neglected diseases, using both small-molecule and biologic/vaccine approaches. AstraZeneca, with our strategic partners, has one of the world’s largest antibacterial pipelines targeting serious bacterial infections. Our partnership interests also include: viral infections such as respiratory viruses (e.g flu, RSV), HCV, HBV and herpes family viruses, as well as systemic fungal infections, and diagnostics. Novel vaccines to address bacterial and viral infections with limited current treatment options are also of interest. We aim to deliver solutions for diseases of the developing world (viral, parasitic and bacterial) through innovative partnerships with academics, NGOs and peer companies.
Partnering leadership team
| Small molecule business development | R&D Strategy Head | Biologics business development |
|---|---|---|
|
VP SPBD, Infection and PHB |
VP Strategy, Infection |
Associate Director, Business Development |
Neuroscience
Neuroscience is an area with huge unmet medical need. Our virtualised Neuroscience model is pioneering new ways to share cost, risk and reward with research partners to deliver effective treatments for CNS disorders and pain. We are working with a network of external partners to progress new projects flexibly and quickly from discovery through early development. We are interested in small and large molecule research to discover and develop new treatments in neurology, psychiatry and pain.
Partnering leadership team
| Small molecule business development | R&D Strategy Head | Biologics business development |
|---|---|---|
|
VP New Business Development, Neuroscience |
VP Strategy, Neuroscience |
Senior Manager, Business Development |
Personalised healthcare
Our Personalised Healthcare and Biomarkers (PHB) group aims to create superior outcomes for patients, prescribers and payers by finding the biomarkers and diagnostics that ensure we deliver effective medicines that target a selected patient population. We are looking for additional biomarker capabilities that can deliver clinically meaningful segmentation of therapeutic response, including methodology for patient selection, disease identification, and pharmacological assessment. We are also looking for external partners to identify, validate, and manufacture diagnostics to regulatory standards.
Partnering leadership team
| Small molecule business development | R&D Strategy Head | Biologics business development |
|---|---|---|
|
Executive Business Development Director, Personalised Healthcare |
VP Strategy, PHB |
Senior Director, Business Development |
Science & Technology
The Science and Technology team works across therapeutic areas and functions to identify, evaluate, and secure opportunities in key areas of technology that will enhance the quality, effectiveness and productivity of our research. Key areas of interest include predictive safety and predictive efficacy platforms, target validation tools and technologies, novel HTS/lead generation approaches, novel chemical libraries with evidence of biological relevance, stem cell biology and, novel technologies for antibodies and vaccines.
Partnering leadership team
| Small molecule business development | R&D Strategy Head | Biologics business development |
|---|---|---|
|
Executive Business Development Director, STL |
n/a |
Senior Director, Business Development |
AstraZeneca leaders discuss Research and Business development strategy for Oncology
Tim Herpin, VP SPBD Oncology and STL, and Susan Galbraith, Head of Oncology iMed, discuss AstraZeneca's R&D and Business Development strategy in Oncology.
Pioneering new ways of working. Interview with Mike Poole, Head of our Neuroscience iMed
Our virtual Neuroscience iMed is an innovative approach to collaborating on new treatments for diseases of the brain, including Alzheimer’s disease which affects 26 million people.